Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage
oncology and dermatology biopharmaceutical company, announced today that
Dr. Sanjiv Agarwala, in his presentation at the Seventh International
Symposium on Melanoma and Other Cutaneous Malignancies on March 12,
2010, commented on the involvement of the immune system in response to
PV-10 therapy and its role in the “bystander effect” in treating
metastatic melanoma. Dr. Agarwala’s presentation, entitled
“Chemoablation in Melanoma: An Update,” was given in the session
entitled “Unique Approaches to Melanoma Therapy.”
“I look forward to seeing the
results of this research so we can fully understand the potential PV-10
may have in treating not only melanoma, but also other indications in
oncology.”
Dr. Agarwala, Chief, Medical Oncology and Hematology at St. Luke’s
Hospital and Health Network in Bethlehem, PA, and Principal Investigator
for Provectus’s Phase 2 PV-10 trial site at St. Luke’s, noted, “PV-10 is
of particular interest to me as an oncologist because it appears to
recruit immune cells to the ablation site, leading to the potential of a
systemic benefit. Efficacy data from Phase 1 and from the current Phase
2 study demonstrate a close correlation between objective response in
treated lesions and response in uninjected lesions. Survival data from
both studies further support a conclusion that patients that respond
well to PV-10 respond well overall.”